Project Details
Description
Abstract
Depression and anxiety during pregnancy affect over 10% of women with 6-8% of pregnant women receiving a
prescription for a selective serotonin reuptake inhibitor (SSRI) antidepressant. Sertraline is the most commonly
prescribed SSRI in women of reproductive years. However, there remains limited information for optimizing its
treatment during pregnancy. Sertraline shows large inter-individual variability although studies generally suffer
from small sample sizes and inconsistent observations. Physiological changes accompanying pregnancy can
alter drug pharmacokinetics (e.g., clearance) which can significantly affect steady-state concentrations of
medications, supporting the need for dose adjustments in order to maintain pre-pregnancy drug exposure. Our
objective is to quantify the contribution of sertraline pharmacokinetic exposure to maternal health and
obstetrical/neonatal outcomes. The Women’s Mental Health Program database contains prospectively
collected data from more than 2,500 individuals with neuropsychiatric illnesses across more than 15,000
unique visits during the perinatal and postpartum periods. Sertraline and metabolite concentrations along with
maternal symptoms and obstetrical/neonatal outcome information will be analyzed via
pharmacokinetic/pharmacodynamic modeling enabling characterization of the relationships between changes
in sertraline exposure with maternal symptoms of depression and neonatal outcomes during pregnancy and
postpartum. Results from this project will support refinement of dosing strategies and evidence-based
personalized treatment planning for the use of sertraline during pregnancy. The application of pharmacokinetic-
guided dosing will result in enhanced prevention of disease-related symptoms and improved maternal and
child health. This project will provide the foundation for investigation of other antidepressants and psychotropic
medications used during pregnancy.
Status | Active |
---|---|
Effective start/end date | 8/18/22 → 7/31/24 |
Funding
- Eunice Kennedy Shriver National Institute of Child Health and Human Development: $189,233.00
- National Institute of Child Health and Human Development: $223,466.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.